Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tamara Wright

Physician Assistant Wenatchee, WA Physician Assistant

NPI 1710911839 CMS profile 10960627

820 N Chelan Ave, Wenatchee, WA 98801

Open in the dashboard

General payments

$6,361

351 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tamara Wright of Wenatchee, WA is reported in the CMS Open Payments database as having received $6,361 across 351 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $824 44
2024 General $1,093 64
2023 General $1,538 75
2022 General $1,592 81
2021 General $1,314 87

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tamara Wright
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Tamara Wright were reported at $824. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Tamara Wright Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,314 $132 $37–$438 $132
2022 $1,592 $155 $48–$522 $149
2023 $1,538 $167 $52–$557 $160
2024 $1,093 $178 $55–$600 $164
2025 $824 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $3,053 188 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $381 22 payments
  3. Lilly USA, LLC $368 18 payments
  4. Xeris Pharmaceuticals, Inc. $278 16 payments
  5. Sanofi-Aventis U.S. LLC $224 12 payments
  6. Tandem Diabetes Care, Inc. $209 8 payments
  7. Dexcom, Inc. $187 5 payments
  8. Amgen Inc. $185 12 payments
  9. Ascensia Diabetes Care US Inc. $182 3 payments
  10. Insulet Corporation $149 7 payments
  11. Other $1,142 60 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,349 350 payments
  2. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. RYBELSUS $2,636 161 payments
  2. Ozempic $2,602 159 payments
  3. Wegovy $297 24 payments
  4. MOUNJARO $256 10 payments
  5. JARDIANCE $255 15 payments
  6. GVOKE PFS $157 10 payments
  7. EVENITY $152 10 payments
  8. Omnipod $149 7 payments
  9. SOLIQUA 100/33 $139 7 payments
  10. Prolia $137 9 payments
  11. Other $2,214 113 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 62 drugs

Part D claims

3,481

Median for Physician Assistant: 241

Drug cost

$1,598,714

Median for Physician Assistant: $4,110

Branded share of claims

61%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 205 $280,921
Mounjaro Tirzepatide Brand 162 $225,120
Jardiance Empagliflozin Brand 130 $136,301
Tresiba Flextouch U-200 Insulin Degludec Brand 116 $122,006
Humalog Kwikpen U-200 Insulin Lispro Brand 29 $70,912
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 53 $69,127
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 43 $64,983
Trulicity Dulaglutide Brand 52 $64,640
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 41 $57,740
Farxiga Dapagliflozin Propanediol Brand 40 $49,166

The 10 drugs with the highest cost, of 62 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RYBELSUS
  • Novo Nordisk Inc $207
$207 37 —
Ozempic
  • Novo Nordisk Inc $207
$207 205 —
Wegovy
  • Novo Nordisk Inc $94
$94 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $74
  • Lilly USA, LLC $7
$82 130 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $60
$60 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

351 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record